huCD38-CHO-S is primarily used in immunotherapeutic research, particularly in the development and testing of monoclonal antibodies targeting CD38. It serves as a critical reagent in assays to evaluate antibody binding affinity, specificity, and functional activity such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Due to its role in mimicking the human CD38 antigen, it is employed in preclinical studies for hematologic malignancies, including multiple myeloma and certain lymphomas. The molecule supports the screening and optimization of therapeutic antibodies and biosimilars, and is also utilized in immunoassay development, target validation, and pharmacokinetic studies. Its application accelerates the translation of anti-CD38 therapies from research to clinical evaluation.